Stay Ahead. Stay Informed. Know More. In Less. Kolkata's #1 news channel, trusted across India for fast, credible news from India and around the world.

Poly Medicure Posts Rs 930.8 Million Profit in Q1 FY26, Revenue Touches Rs 4.03 Billion

Swarnadwip Nath Published Aug 08, 2025, 03:30 PM Updated Sep 18, 2026, 11:54 AM

Poly Medicure Ltd, a leading manufacturer of medical devices and consumables, has reported a consolidated net profit of Rs 930.8 million for the quarter ended June 2025. The company also posted revenue from operations of Rs 4.03 billion, reflecting robust demand across domestic and international markets. The Q1 performance underscores Poly Medicure’s strategic focus on product innovation, export expansion, and operational efficiency.

With a diversified portfolio spanning infusion therapy, blood management, and dialysis products, the company continues to benefit from rising healthcare infrastructure investments and growing demand for quality medical consumables.

Key Performance Highlights for Q1 FY26

- Consolidated net profit stood at Rs 930.8 million, driven by strong export volumes and margin expansion

- Revenue from operations reached Rs 4.03 billion, supported by broad-based growth across product categories

- EBITDA margins improved due to cost optimization and favorable product mix

- The company maintained a healthy order book, with increased traction in Europe, Asia, and Latin America

Segment-Wise Business Overview

1. Infusion and Blood Management

- Core segments contributed significantly to revenue, with sustained demand from hospitals and clinics

- New product launches in IV cannulas and blood collection systems enhanced market share

2. Dialysis and Renal Care

- Dialysis consumables saw double-digit growth, supported by rising chronic kidney disease cases

- Strategic partnerships with healthcare providers boosted recurring sales

3. Export Markets

- Exports accounted for over 60% of total revenue, with strong performance in Europe and Middle East

- Regulatory approvals in new geographies opened up fresh revenue streams

Operational Efficiency and Cost Management

Poly Medicure’s profitability was supported by disciplined execution and lean manufacturing:

- Automation and process improvements reduced production costs and enhanced throughput

- Raw material sourcing was optimized through long-term contracts and vendor consolidation

- Logistics and distribution efficiencies helped maintain delivery timelines and reduce overheads

Industry Trends and Competitive Landscape

The company’s performance aligns with broader healthcare sector trends:

- Rising demand for single-use medical devices due to infection control protocols

- Increased government spending on public health infrastructure and hospital capacity

- Poly Medicure’s focus on quality and compliance gives it an edge over smaller regional players

Investor Sentiment and Market Response

The Q1 results have reinforced investor confidence:

- Poly Medicure’s shares have remained stable, reflecting consistent earnings and growth visibility

- Analysts expect continued momentum in H2 FY26, especially with new product launches and geographic expansion

- The company’s strong balance sheet and low debt levels support long-term sustainability

Outlook and Strategic Priorities

Poly Medicure is well-positioned to capitalize on emerging opportunities:

- Expanding manufacturing capacity in India and overseas to meet rising demand

- Investing in R&D for next-generation medical devices and consumables

- Strengthening distribution networks and digital platforms for better customer engagement

Conclusion

Poly Medicure Ltd’s Q1 FY26 results reflect its operational strength and strategic clarity in a competitive healthcare landscape. With Rs 4.03 billion in revenue and Rs 930.8 million in net profit, the company has demonstrated its ability to deliver consistent growth and profitability. As it deepens its market reach and enhances product innovation, Poly Medicure is poised to play a pivotal role in India’s medical device sector and beyond.

Sources: Reuters, Moneycontrol, Business Standard

Stay Ahead – Explore Now! No news available